Zacks Investment Research upgraded shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) from a hold rating to a buy rating in a research report released on Friday. They currently have $5.25 target price on the biotechnology company’s stock.

According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “

Several other research firms have also recently weighed in on ZIOP. HC Wainwright set a $10.00 price objective on shares of ZIOPHARM Oncology and gave the stock a buy rating in a research report on Tuesday, August 1st. ValuEngine cut shares of ZIOPHARM Oncology from a hold rating to a sell rating in a research report on Monday, August 14th. Finally, BidaskClub upgraded shares of ZIOPHARM Oncology from a sell rating to a hold rating in a research report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $12.58.

ZIOPHARM Oncology (NASDAQ ZIOP) traded down $0.25 during mid-day trading on Friday, reaching $4.30. 3,309,900 shares of the company traded hands, compared to its average volume of 1,335,318. ZIOPHARM Oncology has a 1 year low of $4.16 and a 1 year high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The company had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. During the same quarter last year, the firm earned ($0.11) EPS. The business’s revenue for the quarter was up .0% on a year-over-year basis. analysts expect that ZIOPHARM Oncology will post -0.54 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/11/13/ziopharm-oncology-inc-ziop-lifted-to-buy-at-zacks-investment-research.html.

In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper bought 6,440 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was bought at an average price of $4.68 per share, for a total transaction of $30,139.20. Following the transaction, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 10.40% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Amalgamated Bank raised its position in shares of ZIOPHARM Oncology by 12.9% during the 2nd quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 1,924 shares during the last quarter. Oppenheimer & Co. Inc. raised its position in shares of ZIOPHARM Oncology by 50.0% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 6,000 shares during the last quarter. BB&T Securities LLC acquired a new position in shares of ZIOPHARM Oncology in the 2nd quarter valued at $112,000. Adell Harriman & Carpenter Inc. acquired a new position in shares of ZIOPHARM Oncology in the 3rd quarter valued at $141,000. Finally, Principal Financial Group Inc. grew its holdings in shares of ZIOPHARM Oncology by 7.5% in the 2nd quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 1,673 shares during the period. Institutional investors own 41.88% of the company’s stock.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.